(Q37776148)

23 August 2017

1 reference

title

Effect of systemic medications on onset and progression of diabetic retinopathy (English)

1 reference

23 August 2017

2

Jerry D. Cavallerano

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20664533

11 June 2024

3

Jennifer K. Sun

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20664533

11 June 2024

author name string

Lloyd Paul Aiello

series ordinal

5

1 reference

23 August 2017

Paolo S. Silva

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20664533

11 June 2024

Lloyd M. Aiello

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20664533

11 June 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20664533

11 June 2024

publication date

27 July 2010

1 reference

full work available at URL

23 August 2017

http://www.nature.com/articles/nrendo.2010.122

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2010.122

http://www.nature.com/articles/nrendo.2010.122.pdf

11 June 2024

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2010.122

Nature Reviews Endocrinology

11 June 2024

published in

1 reference

23 August 2017

volume

6

1 reference

23 August 2017

issue

9

1 reference

23 August 2017

page(s)

494-508

1 reference

https://scigraph.springernature.com/pub.10.1038/nrendo.2010.122

23 August 2017

exact match

0 references

cites work

Nonenzymatic glycosylation and the pathogenesis of diabetic complications

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

The U.K. Prospective Diabetes Study. A review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy

21 January 2018

2 references

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

21 January 2018

12 December 2020

Glitazones: clinical effects and molecular mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

PPARgamma Agonists: Potential as Therapeutics for Neovascular Retinopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Aspirin effects on the development of cataracts in patients with diabetes mellitus. Early treatment diabetic retinopathy study report 16

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Ticlopidine Treatment Reduces the Progression of Nonproliferative Diabetic Retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

The Cataract National Dataset electronic multicentre audit of 55,567 operations: antiplatelet and anticoagulant medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Standards of medical care in diabetes--2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

The IDF Diabetes Atlas: providing evidence, raising awareness and promoting action

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Improvements in life expectancy in type 1 diabetes patients in the last six decades

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: the 50-year medalist study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Characteristics of Type 1 diabetes of over 50 years duration (the Golden Years Cohort)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Fear of visual loss in patients with diabetes: results of the prevalence of diabetic eye disease in Tayside, Scotland (P-DETS) study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

The prevalence of diabetic retinopathy among adults in the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

The association between retinopathy, nephropathy, cardiovascular disease and long-term metabolic control in type 1 diabetes mellitus: a 5 year follow-up study of 442 adult patients in routine care

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Systemic considerations in the management of diabetic retinopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

The sorbitol pathway and the complications of diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

The role of protein kinase C in the development of the complications of diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Role of oxidative stress in diabetic complications: a new perspective on an old paradigm

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Diabetic glycemic control and retinal blood flow

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Photocoagulation for Diabetic Macular Edema

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Retinopathy and vision loss in insulin-dependent diabetes in Europe. The EURODIAB IDDM Complications Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

10-year follow-up of intensive glucose control in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Relevance of the vascular effects of insulin in the rationale of its therapeutical use.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Blood glucose control and the evolution of diabetic retinopathy and albuminuria. A preliminary multicenter trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Effect of 1 year of near-normal blood glucose levels on retinopathy in insulin-dependent diabetics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Irreversible progression of severe retinopathy in young type I insulin-dependent diabetes mellitus patients after improved metabolic control

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Strict metabolic control and retinal blood flow in diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Sustained regression of florid diabetic retinopathy in a patient with Donohue syndrome (leprechaunism).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Progressive retinopathy with improved control in diabetic dwarfism (Mauriac's syndrome)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Rosiglitazone and delayed onset of proliferative diabetic retinopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Considerations for management of fluid dynamic issues associated with thiazolidinediones

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Diabetic macular edema associated with glitazone use.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Glitazone use associated with diabetic macular edema

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Metformin inhibits inflammatory angiogenesis in a murine sponge model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Metformin decreases angiogenesis via NF-kappaB and Erk1/2/Erk5 pathways by increasing the antiangiogenic thrombospondin-1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Suppression of Fas-FasL-induced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Fibrates and microvascular complications in diabetes--insight from the FIELD study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Non-lipid-related effects of statins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

A three-year trial of atromid therapy in exudative diabetic retinopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Efficacy and safety of etofibrate in patients with non-proliferative diabetic retinopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Residual microvascular risk in diabetes: unmet needs and future directions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Effects of medical therapies on retinopathy progression in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Angiotensin and diabetic retinopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Relationship of blood pressure to retinal vessel diameter in type 1 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Renal and retinal effects of enalapril and losartan in type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Platelet adhesion and aggregation in diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Increased prevalence of microthromboses in retinal capillaries of diabetic individuals

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Aspirin use and the prevention of acute ischemic cranial nerve palsy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Salicylate-based anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Aspirin at low-intermediate concentrations protects retinal vessels in experimental diabetic retinopathy through non-platelet-mediated effects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Prevalence of ocular hemorrhage in patients receiving warfarin therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Safety of continuing warfarin therapy during cataract surgery: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Anticoagulation with warfarin in vitreoretinal surgery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Maintenance of warfarin anticoagulation for patients undergoing vitreoretinal surgery.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Safety of intravitreal injections in patients receiving warfarin anticoagulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Relationship between anticoagulant medication and massive intraocular hemorrhage in age-related macular degeneration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Digoxin inhibits retinal ischemia-induced HIF-1alpha expression and ocular neovascularization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Digitalis, a targeted therapy for cancer?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

High-throughput screening identifies cardiac glycosides as potent inhibitors of human tissue kallikrein expression: implications for cancer therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Plasma kallikrein mediates angiotensin II type 1 receptor-stimulated retinal vascular permeability

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Targeting intraocular neovascularization and edema--one drop at a time

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

DIABETIC RETINOPATHY AND RHEUMATOID ARTHRITIS

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Salsalate improves glycemia and inflammatory parameters in obese young adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Preliminary assessment of celecoxib and microdiode pulse laser treatment of diabetic macular edema

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Randomized trial of peribulbar triamcinolone acetonide with and without focal photocoagulation for mild diabetic macular edema: a pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Intravitreal triamcinolone for refractory diabetic macular edema

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

31 March 2020

To mask or not to mask.

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Role of steroids in the management of diabetic macular edema and proliferative diabetic retinopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Independent effects of complement factor H Y402H polymorphism and cigarette smoking on risk of age-related macular degeneration.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Pharmacokinetics of intravitreal ranibizumab (Lucentis).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Pharmacokinetics of intravitreal bevacizumab (Avastin)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Bevacizumab in the treatment of colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Cerebrovascular accidents in ranibizumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Systemic administration of HMG-CoA reductase inhibitor protects the blood-retinal barrier and ameliorates retinal inflammation in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.122

Intravitreal injection of triamcinolone for diffuse diabetic macular edema

31 March 2020

1 reference

12 December 2020

A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema

1 reference

12 December 2020

Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy. The TIMAD Study Group

1 reference

12 December 2020

Co-management of patients with hypertension or diabetes

1 reference

12 December 2020

Insulin-induced vascular endothelial growth factor expression in retina

1 reference

12 December 2020

Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema

1 reference

12 December 2020

[Regression of hard exudates in diabetic background retinopathy in therapy with etofibrate antilipemic agent]

1 reference

12 December 2020

Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group

1 reference

12 December 2020

Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.

1 reference

12 December 2020

The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial

1 reference

12 December 2020

Hyperglycemia impairs retinal oxygen autoregulation in normal and diabetic dogs

1 reference

12 December 2020

Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial

1 reference

12 December 2020

Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group

1 reference

12 December 2020

Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group

1 reference

12 December 2020

Factors influencing the onset and progression of diabetic retinopathy in subjects with insulin-dependent diabetes mellitus

1 reference

12 December 2020

Four risk factors for severe visual loss in diabetic retinopathy. The third report from the Diabetic Retinopathy Study. The Diabetic Retinopathy Study Research Group

1 reference

12 December 2020

Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. The DAMAD Study Group

1 reference

12 December 2020

Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators

1 reference

12 December 2020

A controlled trial of Atromid therapy in exudative diabetic retinopathy

1 reference

12 December 2020

Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group

1 reference

12 December 2020

Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group

1 reference

12 December 2020

Effect of rapid glycemic control on progression of diabetic retinopathy

1 reference

12 December 2020

Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.

1 reference

12 December 2020

Double-blind trial of Atromid-S in exudative diabetic retinopathy.

1 reference

12 December 2020

The Journal of Clinical Endocrinology and Metabolism

61

81

4059

K Cusi

1996

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2010.122

11 June 2024

Identifiers

1 reference

23 August 2017

1 reference